Adagio Medical Receives U.S. Food and Drug Administration IDE Approval to Evaluate Next-Generation vCLAS® Ventricular Ablation System

Adagio Medical Secures U.S. Food and Drug Administration IDE Approval to Study Its Next-Generation vCLAS® Ventricular Ablation System Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio”), a medical technology company focused…

Read MoreAdagio Medical Receives U.S. Food and Drug Administration IDE Approval to Evaluate Next-Generation vCLAS® Ventricular Ablation System

Cognito Therapeutics Partners with Initiative to Replace “Dementia” Terminology Across Communications

Cognito Therapeutics Collaborates with Initiative to Replace the “D-Word,” Committing to Remove “Dementia” from All Communications Cognito Therapeutics, a late clinical-stage neurotechnology company focused on developing non-invasive therapies for neurodegenerative…

Read MoreCognito Therapeutics Partners with Initiative to Replace “Dementia” Terminology Across Communications

United Therapeutics Corporation Receives U.S. Food and Drug Administration RMAT Designation for miroliverELAP® in Acute Liver Failure

United Therapeutics Corporation Receives U.S. Food and Drug Administration Regenerative Medicine Advanced Therapy (RMAT) Designation for miroliverELAP® in the Treatment of Acute Liver Failure United Therapeutics Corporation (Nasdaq: UTHR), a…

Read MoreUnited Therapeutics Corporation Receives U.S. Food and Drug Administration RMAT Designation for miroliverELAP® in Acute Liver Failure
VION Biosciences

VION Biosciences Completes Acquisition of CTL to Enhance Functional Immune Monitoring Capabilities

VION Biosciences Completes Acquisition of CTL, Bolstering Its Functional Immune Monitoring Capabilities VION Biosciences (“VION”), a life sciences company focused on building differentiated capabilities across research, diagnostics, and drug development…

Read MoreVION Biosciences Completes Acquisition of CTL to Enhance Functional Immune Monitoring Capabilities